Two months ago, Medicare started letting eligible seniors get Wegovy and similar obesity drugs for fifty bucks a month. CVS and Walgreens have each filled around 100,000 prescriptions under the program since July, and Walmart says its numbers are growing week over week at more than 5,000 locations. For a program that technically shouldn't exist under current law, it's doing pretty well.
Wait, Medicare Can't Cover This. So How Is It Covering This?
Here's the thing about the Bridge program: federal law explicitly bars Medicare from paying for weight loss drugs. Full stop. So the administration found a workaround, which is either creative governance or legal gymnastics depending on how generous you're feeling.
The trick, as NPR reports, is in the framing. Medicare will cover the drug if the patient has obesity combined with a qualifying condition, like high blood pressure that's hard to control. You're not treating obesity, officially. You're treating the complicated, expensive, life-shortening mess that obesity causes. It's a distinction that would impress a tax attorney.
The program runs through the end of 2027, and it comes with its own exclusion logic that will make your head spin. If you have sleep apnea or Type 2 diabetes, you don't qualify for Bridge, because Medicare Part D is supposed to cover GLP-1 drugs for those conditions already. So you have to be sick enough to qualify, but not too sick in the wrong way. American healthcare, ladies and gentlemen.
The Numbers Are Real and They're Coming In Fast
CVS told NPR it crossed 100,000 Bridge prescriptions filled as of mid-August. Walgreens told NPR the same. That's at minimum 200,000 prescriptions from just two chains, in less than two months, for a program that pharmacies had to scramble to even prepare for.
Walgreens chief pharmacy officer Rick Gates told NPR the stores stocked extra Wegovy, Zepbound, and Foundayo ahead of the July launch. "I think there's been a little bit more uptake than we even expected," Gates said, which is pharmacist for "we did not see this coming."
About half of Walgreens' Bridge patients had never taken a GLP-1 before, Gates added. That matters. These aren't just people switching from a different coverage path. This is genuinely new access for people who previously couldn't afford it. CMS Administrator Mehmet Oz claimed in a late July post on X that 250,000 beneficiaries had signed up, though NPR notes it's unclear how many actually cleared the prior authorization hurdle to get their prescriptions filled.
What 4 Million Eligible Seniors Actually Means
Before Bridge launched, Medicare estimated roughly 4 million recipients could qualify for the program. Jeremy Shane, a nonresident scholar at the USC Leonard D. Schaeffer Institute for Public Policy and Government Service, told NPR that if you account for prescriptions filled outside CVS and Walgreens, early participation could represent somewhere between 5% and 10% of the eligible population. In under two months.
That's not a niche pilot. That's demand. The kind of demand that builds political pressure, that creates constituencies, that makes a temporary program very hard to let expire quietly in 2027.
Shane is careful to note that raw cost is the wrong lens for evaluating something like this. He published research concluding that expanding Medicare access to GLP-1 drugs over 10 years could actually reduce overall healthcare spending, because people on these drugs get healthier and need less dialysis, fewer hospitalizations, fewer of the catastrophically expensive interventions that dominate Medicare's budget. "Almost all of Medicare's costs are for people who have multiple chronic conditions," Shane told NPR. The math on prevention is different than the math on the prescription.
The Bill Is Vague and the Range Is Massive
The administration hasn't said what it expects the Bridge program to cost. That is not a great sign of fiscal transparency. The nonpartisan research group KFF stepped in to run the numbers and came up with a range between $1.3 billion and $10 billion over 18 months, depending on how many of those nearly 4 million eligible beneficiaries actually participate.
For context, NPR notes that Medicare Part D spent $181 billion on prescription drugs in 2025. So the Bridge program is somewhere between rounding error and actually significant, depending on uptake. That's a very large margin of uncertainty to be carrying on a program with no stated budget.
The administration's silence on cost projections is conspicuous. You'd think a program designed under an administration loudly obsessed with government spending would come with some kind of number attached. It doesn't. Which tells you something about how this was built, and how seriously anyone has thought through what happens when 2027 rolls around and millions of seniors are mid-treatment on a drug they can afford because of a program that's about to disappear.
The Dingo Take
Two hundred thousand prescriptions in two months, through a program that technically exploits a legal gray zone to exist at all, for drugs that most of these seniors couldn't have afforded six months ago. You are supposed to look at this and ask whether it's sustainable. Fine. Ask that. But also ask what happens to those 200,000 people when the program sunsets in December 2027 and nobody has built a permanent replacement.
The Bridge program is, in the most literal sense, a bridge to nowhere. It has an end date, no confirmed successor, a cost estimate that spans a $9 billion range, and sits on a legal workaround that a future administration or a creative plaintiff could challenge at any time. Shane's long-term value argument is compelling and probably right. It is also not official policy. It is a nonresident scholar at USC making a reasonable case that nobody in charge has committed to acting on.
Here's what the uptake numbers actually prove: when you make these drugs affordable, people use them. The demand was always there. The barrier was always price. Medicare found a way around the price barrier, however awkward and temporary, and seniors showed up in six figures inside of eight weeks. That's not a pilot result. That's an answer. Whether anyone in Washington has the nerve to build something permanent around it is the only question left.
Comments